SPAC Overview
$250M
IPO Size
Failed
Current Status
2021
IPO Year
Timeline Progress
About
A blank-check company formed to complete a business combination with an unidentified target. It intends to seek biotechnology businesses, with a particular focus on oncology therapeutics, platforms and other modalities for managing and treating cancer.
Investment Focus
Biopharmaceuticals
The terms and the filing trail behind Social Capital Suvretta Holdings Corp. II
What the sponsor registered, what the deal actually priced at, and every 8-K that moved it — unit structure, sponsor promote, and the dated lifecycle events, each linked to its filing.
- Unit structure as registered and as priced — price, warrant coverage, rights, trust per unit
- Sponsor promote: founder shares and percentage, private-placement warrants, trust deposit
- The full 8-K lifecycle timeline, each event linked to its filing
- Price history across the unit, share and warrant tickers
- Follow it, and see it change on your watchlist
SPAC Team
Sponsors
Leadership
Underwriters
Extended Team Information
Led by Chamath Palihapitiya of Social Capital and Kishan (a/k/a Kishen) Mehta of Suvretta. The team brings technology investment and company-building experience, healthcare and biotechnology investing expertise, and financial, accounting and public/private market experience.
Key Information
IPO Date
2021-07-01
State of Incorporation
E9
SIC
6770
Failed Date
2023-06-30
SPAC Ticker
DNAB